Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. cordially invites you to visit
2025 Pharmaceutical Ingredients Exhibition (CPHI Japan) in Tokyo, Japan.
We are pleased to invite you to visit CPHI Japan 2025 at booth 6A-07
to talk about the opportunities for co-operation and discuss the cutting-edge trends in the industry.
Exhibition
?
Time: 9-11 April 2025
Venue: Tokyo Big Sight, Tokyo, Japan
Scale: More than 800 exhibitors from 50 countries, expected to attract more than 30,000 professional visitors.
Focus areas: APIs, biological reagents, natural extracts, pharmaceutical technology and regulatory developments.
As a benchmark exhibition for the pharmaceutical industry in Asia,
CPHI Japan brings together the world's top companies and is a core platform for
technological innovation, market insight and supply chain cooperation.
Japan continues to lead the pharmaceutical industry in the direction of
innovation with its leading R&D capabilities and stringent quality standards.
About us
We will bring our core products of local anaesthetics, antiviral, cardiovascular and cerebrovascular, antitumour and veterinary raw materials to show our R&D strength of high purity APIs and intermediates. (Some of our products are shown below, please contact us if you need more products)
| Product name | CAS |
| *Vonoprazan Fumarate | 1260141-27-2 |
| 881681-01-2 | |
| *Letermovir | 917389-32-3 |
| *Dapagliflozin propanediol monohydrate | 960404-48-2 |
| *Crisaborole | 906673-24-3 |
| Sugammadex sodium | 343306-79-6 |
| *Apalutamide | 956104-40-8 |
| *Baloxavir Marboxil | 1985606-14-1 |
| *Lotilaner | 1369852-71-0 |
| *Ruxolitinib Phosphate | 941678-49-5 |
| *Finerenone | 1050477-31-0 |
| *Upadacitinib | 1310726-60-3 |
| *Ozenoxacin | 245765-41-7 |
| *Resmetirom | 920509-32-6 |
| *Fexuprazan HCI | 1902954-87-3 |
| Prilocaine | 721-50-6 |
| Lidocaine HCI | 6108-05-0 |
| Lidocaine | 137-58-6 |
| Ozagrel sodium | 189224-26-8 |
| Celecoxib | 169590-42-5 |
| Ropivacaine HCI | 132112-35-7 |
| Tetracaine HCI | 136-47-0 |
| Tetracaine | 94-24-6 |
| Prilocaine HCI | 1786-81-8 |
| Pramoxine HCI | 637-58-1 |
| Bupivacaine HCI | 73360-54-0 |
| Bupivacaine | 2180-92-9 |
| Articaine HCI | 23964-57-0 |
| Tadalafil | 171596-29-5 |
| Lacidipine | 103890-78-4 |
| Urapidil HCI | 64887-14-5 |
| *Bilastin | 202189-78-4 |
| *Fluralaner | 864731-61-3 |
| *Afoxolaner | 1093861-60-9 |
| *Sarolaner | 1398609-39-6 |
| *Oclacitinib maleate | 1208319-27-0 |
|
Veterinary intermediates |
|
| 4-acetyl-2-methylbenzoic acid | 55860-35-0 |
| 2-AMino-N-(2,2,2-trifluoroethyl)acetaMide hydrochloride | 1171331-39-7 |
| 3',5'-dichloro-2,2,2-trifluoroacetophenone | 130336-16-2 |
| 4-acetyl-1-naphthoic acid | 131986-05-5 |
| 1-[3-Chloro-5-trifluoromethylphenyl]-2,2,2-trifluoroethanone | 1125812-58-9 |
| 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-1-naphthoic acid | 1308362-48-2 |
| Trans-4-aminocyclohexanecarboxylic acid hydrochloride | 27960-59-4 |
| N-methyl-1-((1r,4r)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide maleate | 1640292-55-2 |
|
Baloxavir Marboxil Intermediates |
|
| (R)-7-(benzyloxy)- 3,4,12,12a-tetrahydro- 1H-[1,4]oxazino[3,4- c]pyrido[2,1-f][1,2,4]- triazine-6,8-dione | 1985607-70-2 |
| 3-(Benzyloxy)-4-oxo-4h-pyran-2-carboxylic acid | 119736-16-2 |
| 7,8-difluoro-6,11-dihydro-Dibenzo[b,e]thiepin-11-ol | 1985607-83-7 |
|
Vonoprazan Fumarate Intermediates |
|
| 5-(2-fluorophenyl)-1H-Pyrrole-3-carboxaldehyde | 881674-56-2 |
| Pyridine-3-sulfonyl chloride | 16133-25-8 |
|
Edoxaban Intermediates |
|
| (1S,4S,5S)-4-Bromo-6-oxabicyclo[3.2.1]octan-7-one | 139893-81-5 |
| tert-Butyl [(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate oxalate | 1210348-34-7 |
| tert-butyl (1R,2S,5S)-2-aMino-5-(diMethylcarbaMoyl)cyclohexylcarbaMate | 365998-36-3 |
| 2-bromo-5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine;4-methylbenzenesulfonic acid | 852291-42-0 |
*All our products are not offered in countries where valid patents exist. All responsibility with repect to third parties patent rights in specific countries lies exclusively with the buyers.
*The advanced intermediates of all above APIs are available
We are looking forward to deepening our cooperation with our global partners to mee
t the challenges of the industry and explore the opportunities in the emerging markets.
Welcome to visit us at booth 6A-07. Through the global stage of CPHI Japan,
we would like to build a new future for the pharmaceutical raw material industry together with you!
Contact Us
Tel: +86-531-58897029/7070
Email: market@chsdpharma.com
Website: www.chsdpharma.com
April 2025, Tokyo Ariake, see you there!
END
